Quick Ratio: United Therapeutics (UTHR)

United Therapeutics maintains its leadership through patents for pulmonary hypertension treatment and advancements in bioprinting. However, reliance on a narrow drug portfolio creates a risk of revenue decline upon the entry of generics. Geopolitics also complicates raw material logistics. The ratio of cash and accounts receivable to short-term debt on GURU.Markets reflects financial stability, where 5.67 shows the current volume of the metric.

Fundamental liquidity analysis minimizes the risks of a sudden default during sharp shifts in market conditions. For United Therapeutics (UTHR), which is developing costly xenotransplantation and organ production technologies, maintaining access to immediate resources is critical. This liquidity metric, excluding illiquid assets, removes inventories to assess the ability to cover obligations solely through cash and accounts receivable. The steady growth of the curve confirms the financial stability of the capital.